# Critical Evaluation of APOE4 Cholesterol Synthesis Hypotheses
## Hypothesis 1: SREBP2 Cleavage Dysregulation by Unlipidated APOE4
### Strongest Specific Weakness: Mechanistic Incompatibility
The hypothesis assumes that APOE4's reduced lipid-binding affinity directly impairs SCAP-SREBP2 complex retention at the ER. However, this conflates two mechanistically distinct cholesterol sensing systems.
The canonical SREBP2 pathway operates via SCAP-Insig binding, which is controlled by ER membrane cholesterol levels (Horton et al., 2002; PMID: 11839548). The model does not incorporate a role for secreted apolipoproteins in this process. The cited reference describes *sterol-dependent* regulation—there's no established mechanism by which extracellular or secreted APOE modulates Insig-SCAP binding at the ER membrane.
**The critical missing link:** How does "unlipidated APOE4 fails to sequester the SCAP-SREBP2 complex" at a mechanistic level? Is there a direct APOE-SCAP interaction? Does APOE4's lipid status alter ER membrane composition sufficiently to affect SCAP-Insig affinity? Without specifying this pathway, the hypothesis posits an unknown intermediary.
### Counter-Evidence and Complications
1. **SREBP2 responds to ER cholesterol, not peripheral lipid status.** SREBP2 processing is governed by ER membrane sterol concentration, not by circulating or secreted apolipoprotein levels. There's a substantial literature gap between "APOE4 is poorly lipidated" and "ER membrane cholesterol sensing is altered."
2. **Alternative explanations for elevated SREBP2 targets in AD.** Liang et al. (2022; PMID: 35697673) shows association, not causation. Elevated SREBP2 activity could result from:
- Neuronal loss (decreased cholesterol demand)
- Inflammatory signaling (STAT-mediated effects)
-